phosphorylcholine has been researched along with Local Neoplasm Recurrence in 15 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Perifosine is an alkylphospholipid analog that inhibits or modulates signaling through signal transduction pathways such as Akt, which is enhanced in neuroblastoma (NB) by activation of tyrosine kinase receptors." | 9.24 | Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ( Chin, M; Kato, K; Kawamoto, H; Kosaka, Y; Matsumoto, K; Mugishima, H; Shichino, H, 2017) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 6.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 6.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Perifosine is an alkylphospholipid analog that inhibits or modulates signaling through signal transduction pathways such as Akt, which is enhanced in neuroblastoma (NB) by activation of tyrosine kinase receptors." | 5.24 | Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma. ( Chin, M; Kato, K; Kawamoto, H; Kosaka, Y; Matsumoto, K; Mugishima, H; Shichino, H, 2017) |
| "Perifosine was fixed as a 600 mg load on day 1 followed by 100 mg nightly (single agent MTD) until dose level 7 when the load increased to 900 mg." | 2.94 | Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, I; Holland, EC; Kaley, TJ; Lacouture, ME; Lassman, AB; Ludwig, E; Mellinghoff, IK; Nolan, C; Omuro, A; Panageas, KS; Pentsova, EI, 2020) |
| "Perifosine (PRF) is an oral alkylphospholipid with antineoplastic effects and reasonable tolerability." | 2.90 | Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma. ( Abrey, LE; DeAngelis, LM; Gavrilovic, IT; Holland, EC; Kaley, TJ; Lassman, AB; Mellinghoff, IK; Nolan, C; Panageas, KS, 2019) |
| "Perifosine is an oral alkylphospholipid that inhibits cancer cell growth through decreased Akt phosphorylation." | 2.73 | The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial. ( Cambio, A; Chatta, G; Chee, KG; Evans, CP; Gandara, DR; Lara, PN; Longmate, J; Pan, CX; Pinski, J; Quinn, DI; Twardowski, P, 2007) |
| "Perifosine is an oral alkylphospholipid that inhibits AKT phosphorylation and has shown preclinical antitumor activity in head and neck cancer cell lines and xenografts." | 2.72 | A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer. ( Ansari, R; Argiris, A; Cohen, E; Dancey, J; Esparaz, B; Karrison, T; Lu, Y; Mauer, A; Pins, M; Vokes, E; Wong, S, 2006) |
| "Widespread local recurrence of breast cancer, untreatable by surgery or radiation therapy, can present a serious therapeutic problem predominantly in patients refractory to systemic therapy." | 1.28 | Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients. ( Eibl, H; Hilgard, P; Nagel, G; Peukert, M; Sindermann, H; Unger, C, 1990) |
| " After oral application He-PC was well absorbed from the intestine and metabolized in the liver by phospholipases C and D." | 1.28 | Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo. ( Breiser, A; Damenz, W; Eibl, H; Engel, J; Fleer, EA; Hilgard, P; Kim, DJ; Nagel, G; Unger, C, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (13.33) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 4 (26.67) | 29.6817 |
| 2010's | 5 (33.33) | 24.3611 |
| 2020's | 2 (13.33) | 2.80 |
| Authors | Studies |
|---|---|
| Wada, Y | 1 |
| Okano, K | 1 |
| Sato, K | 1 |
| Sugimoto, M | 1 |
| Shimomura, A | 1 |
| Nagao, M | 1 |
| Matsukawa, H | 1 |
| Ando, Y | 1 |
| Suto, H | 1 |
| Oshima, M | 1 |
| Kondo, A | 1 |
| Asano, E | 1 |
| Kishino, T | 1 |
| Kumamoto, K | 1 |
| Kobara, H | 1 |
| Kamada, H | 1 |
| Masaki, T | 1 |
| Soga, T | 1 |
| Suzuki, Y | 1 |
| Kaley, TJ | 2 |
| Panageas, KS | 2 |
| Pentsova, EI | 1 |
| Mellinghoff, IK | 2 |
| Nolan, C | 2 |
| Gavrilovic, I | 1 |
| DeAngelis, LM | 2 |
| Abrey, LE | 2 |
| Holland, EC | 2 |
| Omuro, A | 1 |
| Lacouture, ME | 1 |
| Ludwig, E | 1 |
| Lassman, AB | 2 |
| Matsumoto, K | 1 |
| Shichino, H | 1 |
| Kawamoto, H | 1 |
| Kosaka, Y | 1 |
| Chin, M | 1 |
| Kato, K | 1 |
| Mugishima, H | 1 |
| Becher, OJ | 2 |
| Millard, NE | 1 |
| Modak, S | 2 |
| Kushner, BH | 2 |
| Haque, S | 1 |
| Spasojevic, I | 1 |
| Trippett, TM | 1 |
| Gilheeney, SW | 1 |
| Khakoo, Y | 1 |
| Lyden, DC | 1 |
| De Braganca, KC | 1 |
| Kolesar, JM | 1 |
| Huse, JT | 1 |
| Kramer, K | 2 |
| Cheung, NV | 2 |
| Dunkel, IJ | 2 |
| Hasegawa, K | 1 |
| Kagabu, M | 1 |
| Mizuno, M | 1 |
| Oda, K | 1 |
| Aoki, D | 1 |
| Mabuchi, S | 1 |
| Kamiura, S | 1 |
| Yamaguchi, S | 1 |
| Aoki, Y | 1 |
| Saito, T | 1 |
| Yunokawa, M | 1 |
| Takehara, K | 1 |
| Okamoto, A | 1 |
| Ochiai, K | 1 |
| Kimura, T | 1 |
| Gavrilovic, IT | 1 |
| Basu, EM | 1 |
| Roberts, SS | 1 |
| Mahieu-Renard, L | 1 |
| Richard, MA | 1 |
| Dales, JP | 1 |
| Buscaylet, S | 1 |
| Lagrassa, S | 1 |
| Grob, JJ | 1 |
| Ragnarsson-Olding, B | 1 |
| Djureen-Mårtensson, E | 1 |
| Månsson-Brahme, E | 1 |
| Hansson, J | 1 |
| Argiris, A | 1 |
| Cohen, E | 1 |
| Karrison, T | 1 |
| Esparaz, B | 1 |
| Mauer, A | 1 |
| Ansari, R | 1 |
| Wong, S | 1 |
| Lu, Y | 1 |
| Pins, M | 1 |
| Dancey, J | 1 |
| Vokes, E | 1 |
| Chee, KG | 1 |
| Longmate, J | 1 |
| Quinn, DI | 1 |
| Chatta, G | 1 |
| Pinski, J | 1 |
| Twardowski, P | 1 |
| Pan, CX | 1 |
| Cambio, A | 1 |
| Evans, CP | 1 |
| Gandara, DR | 1 |
| Lara, PN | 1 |
| Clive, S | 1 |
| Leonard, RC | 1 |
| Unger, C | 3 |
| Peukert, M | 2 |
| Sindermann, H | 2 |
| Hilgard, P | 3 |
| Nagel, G | 2 |
| Eibl, H | 3 |
| Damenz, W | 1 |
| Fleer, EA | 1 |
| Kim, DJ | 1 |
| Breiser, A | 2 |
| Engel, J | 2 |
| von Heyden, HW | 1 |
| Nagel, GA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Phase I Study of Single Agent Perifosine for Recurrent Pediatric Solid Tumors[NCT00776867] | Phase 1 | 38 participants (Anticipated) | Interventional | 2008-10-31 | Completed | ||
| A Phase II Study Of Perifosine In Patients With Recurrent Or Metastatic Head And Neck Cancer[NCT00062387] | Phase 2 | 46 participants (Actual) | Interventional | 2003-05-31 | Terminated (stopped due to Administratively complete.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
8 trials available for phosphorylcholine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Phase I clinical trial of temsirolimus and perifosine for recurrent glioblastoma.
Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Drug Therapy, Combination; Female; Glioblastoma | 2020 |
Phase I study of perifosine monotherapy in patients with recurrent or refractory neuroblastoma.
Topics: Adolescent; Adult; Child; Child, Preschool; Drug Resistance, Neoplasm; Female; Follow-Up Studies; Hu | 2017 |
A phase I study of single-agent perifosine for recurrent or refractory pediatric CNS and solid tumors.
Topics: Adolescent; Antineoplastic Agents; Central Nervous System Neoplasms; Child; Child, Preschool; Drug A | 2017 |
Phase II basket trial of perifosine monotherapy for recurrent gynecologic cancer with or without PIK3CA mutations.
Topics: Adult; Aged; Class I Phosphatidylinositol 3-Kinases; Cohort Studies; Female; Follow-Up Studies; Geni | 2017 |
Phase II trial of an AKT inhibitor (perifosine) for recurrent glioblastoma.
Topics: Adult; Aged; Brain Neoplasms; Female; Follow-Up Studies; Glioblastoma; Humans; Male; Middle Aged; Ne | 2019 |
A phase I/Ib trial targeting the Pi3k/Akt pathway using perifosine: Long-term progression-free survival of patients with resistant neuroblastoma.
Topics: Adolescent; Adult; Antineoplastic Agents; Child; Child, Preschool; Disease-Free Survival; Female; Hu | 2017 |
A phase II trial of perifosine, an oral alkylphospholipid, in recurrent or metastatic head and neck cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers, Tumor; Carc | 2006 |
The AKT inhibitor perifosine in biochemically recurrent prostate cancer: a phase II California/Pittsburgh cancer consortium trial.
Topics: Aged; Androgen Antagonists; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Phosphorylcholine | 2007 |
7 other studies available for phosphorylcholine and Local Neoplasm Recurrence
| Article | Year |
|---|---|
Tumor metabolic alterations after neoadjuvant chemoradiotherapy predict postoperative recurrence in patients with pancreatic cancer.
Topics: Antigens, CD; Carcinoma, Pancreatic Ductal; Carnitine; Chemoradiotherapy; Glutathione; Humans; Neoad | 2022 |
[Treatment of cutaneous metastases of a squamous cell carcinoma of the leg with topical miltefosine].
Topics: Administration, Topical; Aged; Antineoplastic Agents; Carcinoma, Squamous Cell; Female; Humans; Leg; | 2005 |
Loco-regional control of cutaneous metastases of malignant melanoma by treatment with miltefosine (Miltex).
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Humans; Melanoma; Neo | 2005 |
Miltefosine in recurrent cutaneous breast cancer.
Topics: Antineoplastic Agents; Breast Neoplasms; Female; Humans; Neoplasm Recurrence, Local; Phosphorylcholi | 1997 |
Hexadecylphosphocholine in the topical treatment of skin metastases in breast cancer patients.
Topics: Administration, Topical; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Breast Neoplasms; Dr | 1990 |
Hexadecylphosphocholine, a new ether lipid analogue. Studies on the antineoplastic activity in vitro and in vivo.
Topics: Animals; Antineoplastic Agents; Breast Neoplasms; Choline; Drug Screening Assays, Antitumor; Female; | 1989 |
Hexadecylphosphocholine (D 18506) in the topical treatment of skin metastases: a phase-I trial.
Topics: Administration, Topical; Breast Neoplasms; Choline; Drug Evaluation; Female; Humans; Neoplasm Recurr | 1988 |